Attached files
| file | filename |
|---|---|
| EX-31.2 - EXHIBIT 31.2 - ENZON PHARMACEUTICALS, INC. | tm205379d1_ex31-2.htm |
| EX-32.2 - EXHIBIT 32.2 - ENZON PHARMACEUTICALS, INC. | tm205379d1_ex32-2.htm |
| EX-32.1 - EXHIBIT 32.1 - ENZON PHARMACEUTICALS, INC. | tm205379d1_ex32-1.htm |
| EX-31.1 - EXHIBIT 31.1 - ENZON PHARMACEUTICALS, INC. | tm205379d1_ex31-1.htm |
| EX-21.1 - EXHIBIT 21.1 - ENZON PHARMACEUTICALS, INC. | tm205379d1_ex21-1.htm |
| EX-4.1 - EXHIBIT 4.1 - ENZON PHARMACEUTICALS, INC. | tm205379d1_ex4-1.htm |
| 10-K - FORM 10-K - ENZON PHARMACEUTICALS, INC. | tm205379-1_10k.htm |
EXHIBIT 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statements of Enzon Pharmaceuticals, Inc. and Subsidiaries on Form S-3 (No. 333-137723) and Form S-8 (Nos. 333-174099, 333-140282,333-134453, 333-132467, 333-121468, 333-101898, 333-64110, and 333-18051) of our report dated February 19, 2020, on our audits of the consolidated financial statements as of December 31, 2019 and 2018 and for each of the years then ended, which report is included in this Annual Report on Form 10-K to be filed on or about February 19, 2020.
| /s/ EisnerAmper LLP | |
| EISNERAMPER LLP | |
| Philadelphia, Pennsylvania | |
| February 19, 2020 |